Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | DBH | P09172 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333582 | 1.00 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL30413844 | 0.84 | MAPT (0.53) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL3792476 | 0.84 | MAPT (0.53) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL580639 | 0.83 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL29725217 | 0.83 | CA2 (0.47) | MAPTSMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2500053 | 0.83 | MAPT (0.56) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 | |
| SCHEMBL2296988 | 0.83 | CA2 (0.47) | MAPTSMN1; SMN2L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL29559892 | 0.83 | CA2 (0.68) | MAPTALDH1A1KDM4ECA2POLB | |
| SCHEMBL1080853 | 0.83 | CA2 (0.68) | MAPTALDH1A1KDM4ECA2POLB | |
| SCHEMBL2495130 | 0.82 | HTR7 (0.58) | MAPTSMN1; SMN2L3MBTL1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | SHANGHAI MEDICILON INC. (CN) | 2025-09-02 | — | — | US | disclosed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20220259214-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | SHANGHAI MEDICILON INC. (CN) | 2022-08-18 | — | — | US | disclosed |
| CN-112480117-B | Pyrrolopyrazole derivative, preparation method and medical application thereof | 上海美迪西生物医药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-112480118-B | Pyrrolopyrazole derivative, preparation method and medical application thereof | 上海美迪西生物医药股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259214-A1 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | PGC, ABCB11, ATP1A2 | MAPT 4205/4885SMN1; SMN2 4734/4885L3MBTL1 4793/4885 |
| US-12404276-B2 | Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases | GIPR, PGC, GRPR | MAPT 3777/4885SMN1; SMN2 4351/4885L3MBTL1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.